NFCR-Supported Researcher Leads Study Aiming to Understand Which Patients May Respond Best to Immunotherapy
New approach developed by Dr. Rakesh Jain and his research team identifies biomarkers that may indicate which patients will best respond to immune checkpoint blockade therapies. A research team led by NFCR-supported scientist Rakesh K. Jain, PhD, the Andrew Werk Cook Professor of Tumor Biology at Harvard Medical School and…...
Strategic Media Partner
